Advanced in Chronic B-Cell Leukemia (CBCL)

Nathalie Meuleman

Brussels, BRU, BE 
Advanced in Chronic B-Cell Leukemia (CBCL)
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Nathalie Meuleman practices in Brussels, Belgium. Ms. Meuleman is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Her clinical research consists of co-authoring 90 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Female

Locations

Brussels, BRU, Belgium
Other Locations
Anderlecht, BRU, Belgium
Gosselies, WAL 6041, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 2
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

90 Total Publications

First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma.
First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma.
Journal: EJNMMI reports
Published: June 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Meuleman's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile